Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.79 |
| ▸ | SMO | Q99835 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1857334 | 0.99 | HSD11B1 (0.78) | HSD11B1SMOSMN1; SMN2POLBHSD17B10 | |
| SCHEMBL1856848 | 0.94 | HSD11B1 (0.71) | HSD11B1SMOSMN1; SMN2POLBHSD17B10 | |
| SCHEMBL1856847 | 0.94 | HSD11B1 (0.71) | HSD11B1SMOSMN1; SMN2POLBHSD17B10 | |
| SCHEMBL5421718 | 0.90 | HSD11B1 (0.78) | HSD11B1SMOSMN1; SMN2POLBNOTUM | |
| SCHEMBL1858258 | 0.83 | HSD11B1 (1.00) | HSD11B1SMOSMN1; SMN2POLBNOTUM | |
| SCHEMBL28780902 | 0.83 | HSD11B1 (1.00) | HSD11B1SMO | |
| SCHEMBL2072436 | 0.82 | HSD11B1 (0.70) | HSD11B1SMN1; SMN2POLBHSD17B10NOTUM | |
| SCHEMBL2072431 | 0.82 | HSD11B1 (0.70) | HSD11B1SMN1; SMN2POLBHSD17B10NOTUM | |
| SCHEMBL2072432 | 0.82 | HSD11B1 (0.70) | HSD11B1SMN1; SMN2POLBHSD17B10NOTUM | |
| SCHEMBL1859751 | 0.82 | HSD11B1 (0.55) | HSD11B1SMN1; SMN2POLBHSD17B10NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2044057-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008000950-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885SMO 4646/4885SMN1; SMN2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.